Neutralising antibodies are critical in the fight against Covid-19 because they defend cells from infection by the virus. Credit: swiftsciencewriting / Pixabay.

Germany-based firm Siemens Healthineers has received CE mark for its SARS-CoV-2 IgG antibody test, enabling its use across Europe and other regions.

The test has proven to measure neutralising antibodies, which are vital to fighting Covid-19 as they defend cells from viral infection.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The company has submitted an application to the US Food and Drug Administration (FDA) for emergency use authorisation (EUA).

Once vaccines for Covid-19 become available, the fully automated antibody tests can detect whether the vaccination programmes are working or not.

Identifying the presence of these neutralising antibodies and evaluating the level required to protect against future encounters with the virus is essential to analyse a vaccine’s effectiveness, Siemens noted.

An enhanced version of an assay launched recently across the world. The test measures the amount of neutralising antibodies in a patient’s blood sample and delivers quantitative results.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Siemens Healthineers Laboratory Diagnostics president Deepak Nath said: “We targeted the spike protein for our antibody tests, anticipating antibodies to this protein would eventually prove to be neutralising.

“Adequate data is available now to confirm the spike protein antibodies are indeed neutralising, especially those against the spike receptor-binding domain.

“Healthcare providers can feel confident that our test will help them determine whether a patient’s immune system is producing the right antibodies to stop or prevent Covid-19 infection.”

The tests are available globally on the largest installed bases of automated immunoassay analysers.

Siemens Healthineers also has a diagnostic that can help in the prognosis, treatment, and follow-up of Covid-19 patients apart from the antibody, antigen, and molecular tests.